PINE BROOK, N.J.--(BUSINESS WIRE)-- <\/p>\n
Ezose Sciences Inc. announced today that Scott A. Siegel, Ph.D., Vice President, Business Development, has been named Chief Operating Officer, a new position at the company. <\/p>\n
Dr. Siegel will assume broad responsibility for operations at Ezose, which focuses on glycomics research to identify biomarkers for use in drug development and disease management, and to characterize biotherapeutic glycoforms. He will also continue to lead Business Development. In his new role he will continue to report to Kiyoshi Nagata,Ph.D., Chairman andChief Executive OfficerofEzose. <\/p>\n
Scott has made Ezose a partner of choice for healthcare companies and academic institutions that seek to realize the promise of glycomics in their R&D programs, said Dr. Nagata. At the same time, his talents and energies have already supported various operational activities at Ezose. We look forward to the still broader contributions he will make in his new position. <\/p>\n
The naming of a chief operating officer, together with the other appointments we are announcing today, demonstrates our commitment to helping our partners establish glycomics as a basic tool in their biomedical research. <\/p>\n
Dr. Siegel brings to his role more than 25 years of experience in the biotechnology and pharmaceutical industries. Before joining Ezose in 2009 he was Vice President of Corporate Development for Redpoint Bio, a publically traded biotechnology company. Earlier, he held various positions in New Business Development and Worldwide Strategic Marketing at Johnson & Johnson. He has served in R&D capacities at Phytera, Inc., Centocor, Inc., and Becton Dickinson and Co., and as Adjunct Associate Professor of Microbiology at the University of Pennsylvania. Dr. Siegel is one of the inventors of Remicade (Infliximab), a therapy for rheumatoid arthritis and other inflammatory disorders. <\/p>\n
Dr. Siegel earned his Ph.D. in Biochemistry from the State University of New York, Downstate Medical Center, and completed his postdoctoral studies in the Department of Pharmacology at Yale University School of Medicine. <\/p>\n
In other recent appointments, Ezose named: <\/p>\n
About Glycomics <\/p>\n
Glycomics is the study of glycans, the sugar chains that during the biochemical process known as glycosylation become attached to many proteins expressed by human cells. The particular glycans involved may crucially determine the function of the resulting glycoprotein and its role in health and disease. <\/p>\n<\/p>\n
See original here: PINE BROOK, N.J.--(BUSINESS WIRE)-- Ezose Sciences Inc. announced today that Scott A. Continue reading
\nEzose Sciences Announces Appointment of Chief Operating Officer<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"